Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Saskatchewan
• Treatments: Glycopyrrolate; Methacholine Chloride; Muscarinic Antagonists; Tiotropium Bromide

Criteria

Inclusion Criteria:

• male or female asthmatics > 19 years of age

• baseline methacholine PC20 less than or equal to 4mg/ml

• baseline lung function >65% predicted

• non-smoker and less than 10 pack year smoking history

Exclusion Criteria:

• use of anticholinergic within 30 days of Visit 1

• poorly controlled asthma

• pregnant or nursing

• respiratory illness within 4 weeks of Visit 1

• exposure to an agent that triggered asthma worsening (e.g. allergen) within 4 weeks of Visit 1